Skip to main content
. 2023 Mar 9;61(3):2201193. doi: 10.1183/13993003.01193-2022

FIGURE 2.

FIGURE 2

Effect of ecleralimab on allergen-induced early asthmatic response (EAR) and late asthmatic response (LAR) after days 42 and 84 of treatment. Data are presented as mean±se. FEV1: forced expiratory volume in 1 s; AIC: allergen inhalation challenge. *: p<0.05 significant difference between ecleralimab and placebo.